DGX — Q2 2026 Earnings Preview
Setup in one line
Quest reports Q2 2026 on July 23 (BMO) — the pure-play lab peers (Labcorp, Guardant, Exact) all report after DGX (Jul 30–31), so pre-print read-throughs come only from diagnostics-adjacent names that reported Jul 15–16 (ABT beat and raised; UNH/ELV utilization; ISRG procedure volume). DGX does not guide the quarter — it guides the full year and updates it each call — so the print is judged on (1) whether the Q2 beat funds a second FY26 raise, (2) whether ex-partner organic volume holds ~+3.8% and rev/req ex-mix holds ≥+2.5%, and (3) any color on the PAMA data-reporting window (closing Jul 31) and the RESULTS Act, the binary 2027 rate catalyst.
Date note: the confirmed report date is July 23, 2026 (BMO), verified via Quest's IR press release dated 2026-06-17 and corroborated by Zacks, Yahoo Finance, TipRanks and StockTitan — consistent with DGX's late-July pattern (2024-07-23, 2025-07-22). This supersedes the internal earnings calendar's stale "July 28" entry. S&P Global MCP was not connected this session; the date was confirmed against the issuer's own disclosure.
Quest is the textbook leader-stays-leader name in clinical diagnostics: alongside Labcorp it anchors a national reference-lab duopoly, growing above the underlying market on volume and mix, with expanding margins and a serial beat-and-raise cadence. The P&L is driven by (a) organic volume (health-system CoLab wins + base demand), (b) revenue-per-requisition mix (advanced diagnostics and consumer/wellness lifting test complexity), and (c) operating leverage from the INVIGORATE cost/productivity program. The debate is volume quality: reported volume is strong but partner-heavy, so the underlying, higher-value organic engine is what validates the thesis.
Growth trajectory — accelerating and high-quality underneath the mix. The last print (Q1'26, reported 2026-04-21) was a clean beat-and-raise: net revenue $2.90B (+9.2% YoY), adjusted diluted EPS $2.50 (+13.1% YoY, a +5.5% beat — the largest of the trailing 12 quarters), adjusted operating income $447M and adjusted operating margin 15.4% (+10 bps YoY). Total requisition volume grew 10.9%, of which ~7 points came from Corewell/Fresenius; strip them out and organic volume was 3.8% with rev/req ex-mix ~+2.5%. Management raised the FY26 guide after a single quarter — the strongest confidence signal a team can send. Shares rose +4.45% same-session on the print. (Per investing-principles, the price reaction is context only; the fundamental acceleration is the signal.)
Key watch items into Q2 2026:
- Guidance: DGX issues no quarterly guide. The operative bar is the standing, raised FY26 guide — net revenue $11.78B–$11.90B (+6.8–7.8%), adjusted EPS $10.63–$10.83 — plus management's explicit cadence of "just over 49% of revenue and EPS in H1, just over 50% in H2." Off the Q1 base, that cadence implies Q2 of ~$2.95–3.00B revenue and ~$2.78–2.83 adjusted EPS — dead-on with Street. Watch whether the Q2 beat funds a second FY raise.
- Mix / margin — the swing: Corewell (~$250M FY26) and Fresenius (~$80–100M FY26) add ~7 points of volume but drag reported rev/req (mix), and Q2 also absorbs an embedded $7–10M fuel headwind (~$0.05–0.07 EPS) and the Project Nova step-up (~$0.25 FY26 dilution, >60% weighted to H2). The YoY adjusted-margin comp against a strong 16.9% in Q2'25 is the number to watch.
- Advanced diagnostics + consumer: the high-quality growth engine — AD-Detect (Alzheimer's) book "more than doubled" YoY in Q1, Haystack MRD now orderable in all 50 states, Lp(a)/ApoB lift from new AHA guidelines, and questhealth.com growing high-20s%. These lift test-per-req and are the mix-up story.
- PAMA 2027 / RESULTS Act (out-of-guide, binary): the data-reporting window (May 1–Jul 31, 2026) closes days after the print; submissions set 2027 CLFS rates. No 2026 P&L impact. Expect Q2-call color on submission breadth and RESULTS Act progress (80+ cosponsors).
Classification: CONSERVATIVE guider, consistent beater. DGX sets an achievable full-year bar (initial FY26 growth of 6.0–7.1% was set below the Q1 run-rate of +9.2%), excludes all M&A, then steps the guide up through the year. It has beaten adjusted EPS 12-for-12 over the last twelve quarters with widening magnitude. The risk into 7/23 is not demand but a mix/cost quarter that lets DGX merely reaffirm rather than raise again.
How to read DGX "guidance": Quest does not issue quarterly revenue, EPS or margin guidance. It guides the full year and updates it each call, so the right way to grade 7/23 is: did the implied Q2 clear normal seasonality, and — more importantly — did management raise the full-year number again. The standing FY26 guide below was set in February 2026 (Q4'25 call) and raised on the Q1'26 call (2026-04-21).
| FY2026 guided metric | Initial (Q4'25) | Raised (Q1'26) | Mgmt confidence into Q2 |
|---|---|---|---|
| Net revenues | $11.70B–$11.82B (+6.0–7.1%) | $11.78B–$11.90B (+6.8–7.8%) | High — raised |
| Adjusted diluted EPS | $10.50–$10.70 | $10.63–$10.83 | High — +$0.13 |
| Reported diluted EPS | $9.45–$9.65 | $9.58–$9.78 | Raised |
| Cash from operations / capex | ~$1.75B / ~$550M | ~$1.75B / ~$550M | Reaffirmed |
| Operating margin / M&A in guide | Expand vs PY / none | Expand vs PY / none | Reaffirmed |
Classification — CONSERVATIVE (sandbag-and-raise). The raise was funded by the Q1 beat, not by lifting the run-rate: DGX beat Q1 adjusted EPS by ~5.5% and flowed roughly that beat through to the year while retaining conservative back-half assumptions (ACA 30 bps kept despite better-than-modeled Q1 enrollment; a tougher summer/hurricane weather comp; Nova and fuel weighted to H2). Initial FY growth (6.0–7.1%) sits below the Q1 actual run-rate (+9.2%), and the guide excludes all M&A. That is the hallmark of a team that guides to beat — base case for 7/23 is a Q2 beat plus a second FY26 raise, mirroring FY2025's twice-raised-then-beaten cadence.
Consensus snapshot. Q2'26 (current qtr): revenue ~$2.98–3.00B (Zacks ~$2.98B / +7.9% YoY; ChartMill ~$3.00B); adjusted EPS ~$2.81–$2.86 (mid ~$2.83, +8.2% YoY vs $2.62), estimates unchanged over the trailing 30 days. FY2026: revenue ~$11.85B / adjusted EPS ~$10.75 — Street sits essentially on top of the guide midpoint ($11.84B / $10.73), with consensus clustered at the top of the range, itself a signal the market expects another raise. There is no gap to arbitrage on the print; the setup is about the raise, not the headline.
3a. Current quarter (Q2 2026) — consensus vs. Q2 2025 comp
DGX does not guide the quarter, so guide columns are Not Guided; the consensus column shows Street (or cadence-implied) estimates, and the comparison of record is implied YoY vs. the Q2'25 actual. Internal is n/a (no drive/model locations available this session).
| Metric | Q2'25 actual (comp) | Q2'26 consensus / est. | Implied YoY | Framing |
|---|---|---|---|---|
| Net revenue | $2,761M | ~$2.98–3.00B | +8.3% | ~25.2% of FY guide mid; normal seasonality |
| Adjusted diluted EPS | $2.62 | ~$2.83 | +8.2% | ~26.4% of FY adj-EPS mid; sandbagged bar |
| Adjusted operating margin | 16.9% | ~16.4–16.9% | ~flat | Mix + fuel + Nova ramp are the compression risk |
| DIS revenue | $2,699M | ~$2.90–2.92B | +7.5–8.2% | Core lab-services engine |
| Total requisition volume growth | +16.3% (PY, acq-aided) | ~+8–10% | n/m | Corewell/Fresenius ~7 pts of volume |
| Organic volume ex-Corewell/Fresenius | — | ~+3.5–4% | in-line | The true underlying-demand read |
| Revenue per req ex-mix | — | ~+2–2.5% | in-line | Advanced dx / consumer mix-up |
Note — the margin watch. Q2 is DGX's seasonally strongest EPS quarter, and the YoY margin comp is against a strong 16.9% in Q2'25. The Corewell/Fresenius mix drag on reported rev/req, the embedded $7–10M fuel headwind and the Project Nova step-up all land in Q2, so a roughly flat-to-modestly-down YoY adjusted margin is the base case even as management guides full-year margin to expand. Read the beat quality: a raise driven by top-line beat is higher-conviction than one driven by cost control.
3b. Historical quarterly trend (Daloopa) — trajectory over absolutes
| KPI | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 |
|---|---|---|---|---|---|
| Net revenues ($M) | $2,652 | $2,761 | $2,816 | $2,806 | $2,895 |
| Organic revenue growth, total (%) | 2.5% | 5.2% | 6.8% | 6.4% | 9.0% |
| Requisition volume growth (%) | 12.4% | 16.3% | 12.5% | 8.5% | 10.9% |
| Revenue per requisition, total (%) | +0.3% | -0.4% | +0.8% | -0.1% | -1.3% |
| Adjusted operating margin (%) | 15.3% | 16.9% | 16.3% | 15.3% | 15.4% |
| Adjusted diluted EPS ($) | $2.21 | $2.62 | $2.60 | $2.42 | $2.50 |
Interpretation: the through-line is accelerating organic growth (total organic revenue 2.5% → 9.0% over five quarters). The headline rev/req has turned negative (−1.3% in Q1'26) purely on mix — the routine-heavy Corewell/Fresenius volume — while rev/req ex-mix ran ~+2.5% on advanced-diagnostics and consumer test-complexity. Stripping the partners out, the underlying business is doing ~3.8% organic volume and ~+2.5% price/mix, the healthiest combination in the dataset. For Q2, management guided the pattern to be "somewhat consistent with what you saw in Q1," with the second-half margin lift front-loaded to the Fresenius ramp.
3c. FQ+1 (Q3 2026) and FY+1 (FY2026) — no quarterly guide
DGX gives no quarterly point guidance. Q3'26 figures below are cadence-implied off the FY mid (clearly labeled, not company guidance); FY2026 is the standing raised guide the Q2 print will confirm or lift.
| Period | Revenue | Adj. EPS | Basis / note |
|---|---|---|---|
| Q3 2026 (FQ+1) | ~$3.00–3.03B | ~$2.72–2.80 | Cadence-implied vs Q3'25 ($2,816M / $2.60); heaviest Nova drag |
| FY2026 (guide, raised) | $11.78–$11.90B | $10.63–$10.83 | +7.2% / +8.9% YoY at mid; excludes all M&A |
| FY2026 (Street) | ~$11.85B | ~$10.75 | On top of guide mid; clustered at the high end |
The setup in one paragraph: management enters Q2 carrying a raised, conservatively-assumptioned FY26 guide and rising confidence, in its seasonally strongest quarter (Q2 > Q1 > Q3 > Q4 on EPS). The raise after a single quarter is the strongest confidence signal a team can send, and it was accompanied by a quantified half-by-half cadence — a tell of high confidence, since teams uncertain about the back half do not hand the Street a split. The one deliberately hedged posture is the back half itself: management kept the 30 bps ACA headwind despite better-than-modeled Q1 enrollment, baked in a tougher weather comp, and weighted Nova/fuel to H2 — the kind of defensible setup that supports another beat-and-raise if 2H merely comes in normal.
Tone trajectory (stepping up): a clean escalation across seven quarters — steady/reaffirming (Q3'24–Q1'25) → progressively confident with serial raises (Q2'25–Q4'25) → outright bullish with an early-year raise (Q1'26, the most bullish reading of the set). Weather shifted from a "worse than last January" live headwind (Q4'25) to "recovered" (~70% of canceled appointments rebooked) by Q1'26; the Alzheimer's book "more than doubled" YoY; consumer stayed strong (questhealth.com high-20s%). The only genuinely cautious notes are the deliberate 2H conservatism and a new, well-sized $7–10M fuel caveat.
Management-quality read: guidance-accuracy is excellent (adjusted-EPS beat all trailing 12 quarters; FY2025 actual $9.85 topped even the twice-raised guide), the mix bridge is transparent (management volunteers the −1.3% headline rev/req vs +2.5% ex-mix rather than hiding it), and margin-expansion is reaffirmed even while absorbing the low-margin Corewell ramp, Nova dilution and fuel. All three investing-framework management-quality tests pass. The one watch-item is C-suite-adjacent: an Interim VP IR title (Bevec → Haemmerle) — not a business red flag, but a bench change to monitor.
Embedded FY26 assumptions (the swing factors for Q2 and 2H):
~6.6% midpoint growth is almost entirely organic (only ~15 bps of M&A carryover; no prospective M&A). Corewell (~$250M at low-single-digit margin) + Fresenius (~$80–100M) contribute ~7 pts of volume but drag rev/req. Ex-partner rev/req +2.5% assumed to continue; unit price ~flat (±30 bps). Conservative cushions: 30 bps ACA revenue headwind retained; 2H weather assumed negative vs an unusually mild 2H'25; Project Nova ~$0.25 EPS dilution with >60% in H2; $7–10M ($0.05–0.07 EPS) fuel headwind starting Q2. Neutral in-year: no PAMA 2026 rate impact (cuts delayed to 2027).
Post-guidance updates since the Q1'26 call (2026-04-21)
$500M 5.000% senior notes priced (~Apr 27) to refinance the $500M 3.45% notes maturing June 1 — balance-sheet housekeeping, consistent with the "interest expense consistent with 2025" assumption, no change to guide. PAMA reporting window open (May 1–Jul 31) and closing at quarter-end — expect Q2-call color on submission breadth and RESULTS Act progress. Labcorp read-through: LH reaffirmed a strong Q1 (revenue +6%, adj EPS +11%) at Jefferies (Jun 3), a supportive base-lab demand backdrop (DGX grew faster). No red flags: no guidance withdrawal, no CEO/CFO change, no release-date delay, no negative pre-announcement — guidance stands as raised at Q1 into the print.
What to listen for on July 23 (tone tells):
(1) Does a Q2 beat fund a second FY26 raise, and is it top-line-driven vs cost control? (2) Ex-partner organic volume holding ~+3.8% and rev/req ex-mix ≥+2.5%. (3) The YoY adjusted-margin comp against 16.9% — how much do mix + fuel + Nova compress it. (4) Any early ACA disenrollment utilization (the 30 bps is in the guide but unobserved). (5) Advanced-diagnostics and consumer momentum continuing to lift mix. (6) PAMA submission-breadth commentary and RESULTS Act progress — the binary 2027 setup.
| Catalyst | Status / latest KPI | What mgmt / Street expects for Q2 | Direction |
|---|---|---|---|
| Corewell Health CoLab | ~$250M organic rev FY26; hospital channel grew double digits | Baked into guide; SE Michigan JV lab opens 2027; watch continued double-digit hospital revenue | Tailwind |
| Fresenius / Spectra ESRD | ~$80–100M FY26; serves >200k dialysis patients | Volume-heavy, low rev/req; margin approaches enterprise average a year in, H2-skewed — the margin-inflection tell | Tailwind (dilutive early) |
| Advanced diagnostics (5 areas) | >$1B FY25 rev; AD-Detect Alzheimer's book >2x YoY; Haystack MRD now in all 50 states | Lp(a)/ApoB lift from new AHA guidelines; the highest-conviction organic mix-up engine | Tailwind |
| Consumer / wellness | questhealth.com high-20s%; WHOOP/Oura/Function partnerships faster | Margin on par or slightly above enterprise avg; broad-based, feeds test-per-req | Tailwind |
| PAMA / RESULTS Act | Data-reporting window May 1–Jul 31 closes days after print; RESULTS Act 80+ cosponsors | Sets 2027 CLFS rates; broad hospital reporting should push DGX rates up; no 2026 P&L impact | Overhang → resolving |
| Project Nova (order-to-cash) | ~$0.25 EPS dilution FY26; >60% of spend in H2, steps up in Q2 | Q2 is the step-up quarter — a near-term EPS drag; first solution wave fall 2027 | Headwind |
| Fuel / macro cost | $7–10M FY26 (~$0.05–0.07 EPS) at ~$4/gal+ | Starts now, hits Q2 + H2; small, sized, embedded | Headwind |
| ACA disenrollment | 30 bps FY26 revenue drag kept in guide; no impact seen in Q1 | Enrollment good, utilization TBD — potential upside if the 30 bps never materializes | Headwind (hedged) |
| M&A optionality | No M&A in FY26 guide; funnel described as "good" | Health-system outreach + remaining independents; any deal is incremental — a free option | Upside |
| Guidance raise | Already raised at Q1; H1 >49% / H2 >50% split is the yardstick | Bull case = second consecutive raise, extending the beat-and-raise pattern | Watch |
Bull case
A Q2 beat (~$2.83+ vs $2.62 LY) with ex-partner organic volume ~+3.8% and rev/req ex-mix ≥+2.5%, advanced-dx/consumer mix lifting margin enough to fund a second FY26 raise, and constructive PAMA/RESULTS Act color → the beat-and-raise compounder narrative extends, with 2H conservatism providing further raise optionality.
Bear case
The Corewell/Fresenius mix drag plus the embedded fuel and Nova step-up compress the YoY adjusted margin more than modeled, early ACA disenrollment starts to bite, and DGX merely reaffirms rather than raises — a "fine but not blowout" print where the mix/margin debate crowds out the strong organic result.
Contrarian angle (per investing principles): management argues that if the ~9,800 labs that skipped the last PAMA cycle actually report this summer, the market-rate math should point to rate increases in 2027 — while the Street treats PAMA purely as a structural overhang. That is a classic "management sees it, the Street is skeptical" setup, made credible by DGX's clean guidance-accuracy record. The tell will be Q2-call commentary on reporting breadth; the clean fix (RESULTS Act) already has 80+ cosponsors and a positive Energy & Commerce hearing.
Ex-earnings newsflow since the Q1 report (2026-04-21), most recent first. The window is steady and on-strategy — advanced-diagnostics access (Haystack MRD nationwide), consumer-channel expansion (Attunio/Getlabs), supportive sell-side price-target hikes, and a housekeeping notes refinancing. No negative surprises, no M&A of note.
| Date | Item | Earnings read-through |
|---|---|---|
| Jun 30 / early-Jul | Attunio Health selects Quest as national lab backbone for its AI precision-psychiatry platform; integrates Getlabs at-home draw | Extends Quest into behavioral-health testing infrastructure and reinforces the at-home/consumer channel. Incremental, not yet material to numbers, but on-thesis for the advanced-dx + consumer mix-shift. |
| Jun 24, 2026 | NY State (CLEP) approval for Haystack MRD — ctDNA minimal-residual-disease test now orderable in all 50 states | Removes the last state gate on a flagship oncology asset; broadens TAM. A modeled 2027+ growth driver rather than a Q2 mover, but supports the advanced-diagnostics narrative. |
| May 2026 | Sell-side PT hikes (Truist, UBS, Baird, Barclays, BofA); blended PT drifted to ~$220–224 | Constructive Street posture into the print, consistent with the "Buy" consensus and the multi-quarter beat streak. A sentiment tailwind. |
| Apr 27, 2026 | Priced $500M of 5.000% senior notes due 2036 (closed May 6) to repay the $500M 3.45% notes maturing Jun 1 | Refinancing, not new leverage — term-extends the maturity wall at a higher coupon (modest go-forward interest headwind, consistent with the "interest expense consistent with 2025" guide assumption). |
| Feb 10, 2026 (context) | Dividend raised 7.5% to $0.86/qtr (15th consecutive annual increase); +$1B added to buyback authorization | Just outside the window (with Q4'25), noted for completeness — signals capital-return confidence and a durable FCF base. |
Read-through: newsflow since the last report is steady and on-strategy — the two operating items (Haystack MRD nationwide access; Attunio/psychiatry) both build the advanced-diagnostics/consumer growth stack management has been emphasizing, the notes deal is housekeeping, and sell-side sentiment is supportive. No management change, no guidance withdrawal, no regulatory shock. Net setup into Q2 is neutral-to-positive.
Quest is a consistent beater — 12-for-12 on adjusted EPS over the last twelve quarters (100% hit rate) — and, crucially, the beat magnitude is improving. Surprises widened almost monotonically from sub-1% in late 2023 (Q4'23 +0.5%, Q1'24 ~in-line) to +5.5% in Q1'26, the largest of the window. Revenue has likewise beaten in essentially every quarter (4-for-4 in the last year, with the magnitude widening from +2.1% in Q4'25 to +3.1% in Q1'26). Per trajectory-over-absolutes, improving beat magnitude says the underlying business is running ahead of the Street's model, not just clearing a fixed sandbag — a favorable set-up signal into Q2'26.
| Metric | Q2'23 | Q3'23 | Q4'23 | Q1'24 | Q2'24 | Q3'24 | Q4'24 | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adj. EPS surprise | +3.1 | +1.4 | +0.5 | ~0 | +1.7 | +1.8 | +1.8 | +2.3 | +2.4 | +3.6 | +2.9 | +5.5 |
| Revenue surprise | +3.8 | beat | beat | beat | beat | beat | beat | beat | beat | beat | +2.1 | +3.1 |
| Quarter | Adj. EPS actual | Street est. | EPS surprise | Net revenue actual | Result |
|---|---|---|---|---|---|
| 2024 Q2 | $2.35 | $2.31 | +1.7% | $2,397M | Beat |
| 2024 Q3 | $2.30 | $2.26 | +1.8% | $2,488M | Beat |
| 2024 Q4 | $2.23 | $2.19 | +1.8% | $2,621M | Beat |
| 2025 Q1 | $2.21 | $2.16 | +2.3% | $2,652M | Beat |
| 2025 Q2 | $2.62 | ~$2.56 | +2.4% | $2,761M | Beat |
| 2025 Q3 | $2.60 | $2.51 | +3.6% | $2,816M | Beat |
| 2025 Q4 | $2.42 | ~$2.35 | +2.9% | $2,806M | Beat |
| 2026 Q1 | $2.50 | ~$2.37 | +5.5% | $2,895M | Beat |
| 2026 Q2E | pending | ~$2.83 | — | ~$2.99B cons. | Base: beat |
Pattern verdict — consistent beater, improving magnitude. Zero adjusted-EPS misses in 12 quarters — textbook "hits what it guides to." The beat mechanism is deliberate and recurring: a conservative full-year guide set at Q4/Q1, then raised mid-year (FY raised at Q2'24, Q2'25 and again at Q1'26), which structurally produces quarterly beats. The magnitude is widening (trailing-4Q average surprise rose from ~+2.1% at Q3'25 to +5.5% at Q1'26) — the business is running ahead of the model, not just clearing a fixed bar. Setup into 7/23 favors another beat vs the ~$2.83 / ~$2.99B consensus, absent a volume/weather shock; a GAAP-reported basis would show more variance and is not the relevant gauge.
tickers/DGX/data/review_workspaces/2026-07-18/. Fundamentals sourced from Daloopa (company_id 542); consensus from Zacks/ChartMill/Yahoo Finance street color; transcripts Q4'25–Q1'26. Bloomberg, Visible Alpha and S&P Global MCPs, and internal SharePoint/Outlook/OneNote/broker sources, were not connected this session — those steps were best-effort and are flagged where relevant, never fabricated. Per investing-principles, price/market-data commentary is deliberately minimized in favor of fundamentals. Data sourced from Daloopa.